Dr. Daniel Morgenstern, MBChir
Claim this profileHospital for Sick Children
Studies Neuroblastoma
Studies Brain Tumor
15 reported clinical trials
32 drugs studied
Area of expertise
1Neuroblastoma
MYC positive
Stage IV
BRD4 positive
2Brain Tumor
MYC positive
BRD4 positive
BRD3 positive
Affiliated Hospitals
Clinical Trials Daniel Morgenstern, MBChir is currently running
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
More about Daniel Morgenstern, MBChir
Clinical Trial Related4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Daniel Morgenstern, MBChir has experience with
- Dinutuximab
- Lorlatinib
- Cyclophosphamide
- CLR 131
- BMS-986158
- BMS-986378
Breakdown of trials Daniel Morgenstern, MBChir has run
Neuroblastoma
- Magrolimab + Dinutuximab for Relapsed Neuroblastoma and Osteosarcoma
- CLR 131 for Pediatric Cancer
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Brain Tumor
Solid Tumors
Cancer
- Magrolimab + Dinutuximab for Relapsed Neuroblastoma and Osteosarcoma
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
- Tiragolumab + Atezolizumab for Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Morgenstern, MBChir specialize in?
Daniel Morgenstern, MBChir focuses on Neuroblastoma and Brain Tumor. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Daniel Morgenstern, MBChir currently recruiting for clinical trials?
Yes, Daniel Morgenstern, MBChir is currently recruiting for 4 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Daniel Morgenstern, MBChir has studied deeply?
Yes, Daniel Morgenstern, MBChir has studied treatments such as Dinutuximab, Lorlatinib, Cyclophosphamide.
What is the best way to schedule an appointment with Daniel Morgenstern, MBChir?
Apply for one of the trials that Daniel Morgenstern, MBChir is conducting.
What is the office address of Daniel Morgenstern, MBChir?
The office of Daniel Morgenstern, MBChir is located at: Hospital for Sick Children, Toronto, Ontario M5G 1X8 Canada. This is the address for their practice at the Hospital for Sick Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.